Effectiveness of pharmacist intervention for asthma control improvement

European Respiratory Journal

Volumn 31, Issue 4, 2008, Pages 790-799

  Mehuys, E ^a,c   Van Bortel, L ^b   De Bolle, L ^a   Van Tongelen, I ^a   Annemans, L ^a   Remon, J P ^a   Brusselle, G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Adherence; Asthma; Asthma education; Inhalation technique; Pharmacotherapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; THEOPHYLLINE; ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; BELGIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADULT; DRUG SELF ADMINISTRATION; FEMALE; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; PHARMACY;

ADMINISTRATION, INHALATION; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; COMMUNITY PHARMACY SERVICES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PHARMACISTS; SELF ADMINISTRATION; SEVERITY OF ILLNESS INDEX;

EID: 41849134089     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00112007     Document Type: Article

References (35)

1. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
2. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-47.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2006. www.ginasthma.org. Date last updated: July 20, 2007. Date last accessed: November 19, 2007.
4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. Bethesda, National Institutes of Health, 1995; publication no. 95-3659.
5. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. Bethesda, National Institutes of Health, 2002; publication no. 02-3659.
6. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006; 130: Suppl. 1, 65S-72S.
7. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998; 113: 587-592.
8. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000; 117: 542-550.
9. Laforest L, Van Ganse E, Devouassoux G, et al. Influence of patients' characteristics and disease management on asthma control. J Allergy Clin Immunol 2006; 117: 1404-1410.
10. Armour C, Bosnic-Anticevich S, Brillant M, et al. Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. Thorax 2007; 62: 496-502.
11. Barbanel D, Eldridge S, Griffiths C. Can a self-management programme delivered by a community pharmacist improve asthma control? A randomised trial. Thorax 2003; 58: 851-854.
12. Mangiapane S, Schulz M, Muhlig S, Ihle P, Schubert I, Waldmann HC. Community pharmacy-based pharmaceutical care for asthma patients. Ann Pharmacother 2005; 39: 1817-1822.
13. Saini B, Krass I, Armour C. Development, implementation, and evaluation of a community pharmacy-based asthma care model. Ann Pharmacother 2004; 38: 1954-1960.
14. Schulz M, Verheyen F, Muhlig S, et al. Pharmaceutical care services for asthma patients: a controlled intervention study. J Clin Pharmacol 2001; 41: 668-676.
15. Weinberger M, Murray MD, Marrero DG, et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA 2002; 288: 1594-1602.
16. Van Mil JW, Tromp TF. European barriers to the implementation of pharmaceutical care. Int J Pharm 2001; 9: 163-168.
17. Mehuys E, Van Bortel L, Annemans L, et al. Medication use and disease control of asthmatic patients in Flanders: a cross-sectional community pharmacy study. Respir Med 2006; 100: 1407-1414.
18. Global Initiative for Asthma Patient Guide. Wat U en Uw Familie aan Astma Kunnen Doen [What You and Your Family Can Do About Asthma]. National Institutes of Health. Bethesda, National Institutes of Health (NIH), 1995; publication no. 96-3659C.
19. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59-65.
20. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117: 549-556.
21. Radeos MS, Camargo CA Jr. Predicted peak expiratory flow: differences across formulae in the literature. Am J Emerg Med 2004; 22: 516-521.
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
23. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-1288.
24. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115: 1265-1270.
25. World Health Organization and Danish College of Pharmacy Practice. Pharmacy-based asthma services: protocol and guidelines, 1998. www.euro.who.int/ Document/E67662.pdf. Date last updated: 1998. Date last accessed: November 19, 2007.
26. Beunckens C, Molenberghs G, Kenward MG. Direct likelihood analysis versus simple forms of imputation for missing data in randomized clinical trials. Clin Trials 2005; 2: 379-386.
27. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002; 19: 246-251.
28. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46: 712-716.
29. Lindgren S, Bake B, Larsson S. Clinical consequences of inadequate inhalation technique in asthma therapy. Eur J Respir Dis 1987; 70: 93-98.
30. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med 2006; 100: 1479-1494.
31. Cerveri I, Locatelli F, Zoia MC, Corsico A, Accordini S, de Marco R. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1999; 14: 288-294.
32. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
33. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277: 887-891.
34. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-1194.
35. Bonell C, Oakley A, Hargreaves J, Strange V, Rees R. Assessment of generalisability in trials of health interventions: suggested framework and systematic review. BMJ 2006; 333: 346-349.